Lantern Pharma Inc (LTRN)
6.15
+0.66
(+12.02%)
USD |
NASDAQ |
May 03, 16:00
6.19
+0.04
(+0.65%)
After-Hours: 20:00
Lantern Pharma Research and Development Expense (Quarterly): 3.573M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.573M |
| September 30, 2023 | 2.210M |
| June 30, 2023 | 3.558M |
| March 31, 2023 | 2.553M |
| December 31, 2022 | 2.252M |
| September 30, 2022 | 0.7023M |
| June 30, 2022 | 2.989M |
| March 31, 2022 | 2.660M |
| December 31, 2021 | 2.162M |
| September 30, 2021 | 2.964M |
| Date | Value |
|---|---|
| June 30, 2021 | 1.165M |
| March 31, 2021 | 1.279M |
| December 31, 2020 | 1.348M |
| September 30, 2020 | 0.6008M |
| June 30, 2020 | 0.157M |
| March 31, 2020 | 0.1371M |
| December 31, 2019 | 0.1775M |
| September 30, 2019 | 0.2284M |
| June 30, 2019 | 0.3613M |
| March 31, 2019 | 0.186M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.1371M
Minimum
Mar 2020
3.573M
Maximum
Dec 2023
1.636M
Average
1.348M
Median
Dec 2020
Research and Development Expense (Quarterly) Benchmarks
| Eyenovia Inc | 4.065M |
| Cassava Sciences Inc | 18.73M |
| Alpine Immune Sciences Inc | 22.93M |
| Clearside Biomedical Inc | 6.313M |
| Poseida Therapeutics Inc | 42.04M |